{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:37:16Z","timestamp":1774366636678,"version":"3.50.1"},"reference-count":103,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Transplantation offers cure for some haematological cancers, end-stage organ failure, but at the cost of long-term complications. Renal transplantation is the best-known kidney replacement therapy and it can prolong end-stage renal disease patient lives for decades. However, patients after renal transplantation are at a higher risk of developing different complications connected not only with surgical procedure but also with immunosuppressive treatment, chronic kidney disease progression and rejection processes. Various blood disorders can develop in post-transplant patients ranging from relatively benign anaemia through cytopenias to therapy-related myelodysplasia and acute myeloid leukaemia (AML) and post-transplant lymphoproliferative disorders followed by a rare and fatal condition of thrombotic microangiopathy and haemophagocytic syndrome. So far literature mainly focused on the post-transplant lymphoproliferative disease. In this review, a variety of haematological problems after transplantation ranging from rare disorders such as myelodysplasia and AML to relatively common conditions such as anaemia and iron deficiency are presented with up-to-date diagnosis and management.<\/jats:p>","DOI":"10.1093\/ndt\/gfaa219","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T19:20:40Z","timestamp":1595445640000},"page":"409-420","source":"Crossref","is-referenced-by-count":12,"title":["Haematological disorders following kidney transplantation"],"prefix":"10.1093","volume":"37","author":[{"given":"Jolanta","family":"Malyszko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Basak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Batko","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Collegium Medicum, Jagiellonian University, Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3469-8614","authenticated-orcid":false,"given":"Giavambatista","family":"Capasso","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University Luigi Vanvitelli, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Capasso","sequence":"additional","affiliation":[{"name":"Department of Oncology, Livestrong Cancer Institutes, Dell Medical School, The University of Texas, Austin, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Drozd-Sokolowska","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Krzanowska","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Collegium Medicum, Jagiellonian University, Cracow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Kulicki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Matuszkiewicz-Rowinska","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-0766","authenticated-orcid":false,"given":"Maria Jose","family":"Soler","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-9675","authenticated-orcid":false,"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Transplantation, Laboratory of Molecular Immunology, Rega Institute, Katholieke Universiteit Leuven, Belgium"},{"name":"Division of Nephrology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Malyszko","sequence":"additional","affiliation":[{"name":"1st Department of Nephrology and Transplantology, Medical University of Bialystok, Bialystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"2022022612090584700_gfaa219-B1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1681\/ASN.V11suppl_1s1","article-title":"Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation","volume":"11 (Suppl 15","author":"Kasiske","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"2022022612090584700_gfaa219-B2","first-page":"40","author":"World Health Organization: Report of WHO Scientific Group","year":"1968"},{"key":"2022022612090584700_gfaa219-B3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/ndt\/gfn653","article-title":"Anemia management in patients with chronic kidney disease: a position statement by the Anemia Working Group of European Renal Best Practice (ERBP)","volume":"24","author":"Locatelli","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2022022612090584700_gfaa219-B4","first-page":"S1","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2022022612090584700_gfaa219-B5","first-page":"ii1","article-title":"Revised European best practice guidelines for the management of anemia in patients with chronic renal failure","volume":"19(Suppl 2","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2022022612090584700_gfaa219-B6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1432-2277.2012.01513.x","article-title":"Anemia and erythrocytosis in patients after kidney transplantation","volume":"25","author":"Malyszko","year":"2012","journal-title":"Transpl Int"},{"key":"2022022612090584700_gfaa219-B7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12882-019-1244-y","article-title":"Postransplantation anemia: causes, severity and their association with graft and patient survival","volume":"20","author":"Schechter","year":"2019","journal-title":"BMC Nephrol"},{"key":"2022022612090584700_gfaa219-B8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ejim.2015.04.010","article-title":"Predicting the emergence of anemia- A large cohort study","volume":"26","author":"Gafter-Gvili","year":"2015","journal-title":"Eur J Intern Med"},{"key":"2022022612090584700_gfaa219-B9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.transproceed.2004.11.081","article-title":"Iron deficiency- an underrecognized problem in nonanemic and erythrocytic kidney transplant recipients: risks and effects of ACEI and iron treatment","volume":"37","author":"Jimeno","year":"2005","journal-title":"Transplant Proc"},{"key":"2022022612090584700_gfaa219-B10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1309\/AJCPQAX0JFHFS0OA","article-title":"Diagnosis of iron deficiency in patients undergoing hemodialysis","volume":"133","author":"Buttarello","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"2022022612090584700_gfaa219-B11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","article-title":"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation","volume":"102","author":"Ganz","year":"2003","journal-title":"Blood"},{"key":"2022022612090584700_gfaa219-B12","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","article-title":"Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein","volume":"101","author":"Nemeth","year":"2003","journal-title":"Blood"},{"key":"2022022612090584700_gfaa219-B13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2004-12-4855","article-title":"Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels and hepatic function","volume":"106","author":"D\u00e9tivaud","year":"2005","journal-title":"Blood"},{"key":"2022022612090584700_gfaa219-B14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1039\/c0mt00043d","article-title":"Molecular mechanism of intestinal iron absorption","volume":"3","author":"Han","year":"2011","journal-title":"Metallomics"},{"key":"2022022612090584700_gfaa219-B15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/eci.12682","article-title":"Association of hepcidin-25 with survival after kidney transplantation","volume":"46","author":"Eisenga","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"2022022612090584700_gfaa219-B16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000351810","article-title":"GDF15 is related to anemia and hepcidin in kidney allograft recipients","volume":"123","author":"Malyszko","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"2022022612090584700_gfaa219-B17","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/TP.0b013e31828d8489","article-title":"The role of hepcidin-25 in kidney transplantation","volume":"95","author":"Chan","year":"2013","journal-title":"Transplantation"},{"key":"2022022612090584700_gfaa219-B18","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1016\/j.transproceed.2009.08.003","article-title":"A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients","volume":"41","author":"Malyszko","year":"2009","journal-title":"Transplant Proc"},{"key":"2022022612090584700_gfaa219-B19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ajh.20657","article-title":"Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis","volume":"81","author":"Malyszko","year":"2006","journal-title":"Am J Hematol"},{"key":"2022022612090584700_gfaa219-B20","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.transproceed.2006.08.137","article-title":"Hepcidin, an acute-phase protein and marker of inflammation in kidney transplant recipients with and without coronary artery disease","volume":"38","author":"Malyszko","year":"2006","journal-title":"Transplant Proc"},{"key":"2022022612090584700_gfaa219-B21","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/j.transproceed.2014.10.035","article-title":"Parameters influencing blood erythropoietin levels of renal transplant recipients during the early post-transplantation period","volume":"46","author":"Kalantzi","year":"2014","journal-title":"Transplant Proc"},{"key":"2022022612090584700_gfaa219-B22","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1210\/en.2011-2045","article-title":"17beta-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site","volume":"153","author":"Yang","year":"2012","journal-title":"Endocrinology"},{"key":"2022022612090584700_gfaa219-B23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.gene.2012.09.060","article-title":"Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element","volume":"511","author":"Hou","year":"2012","journal-title":"Gene"},{"key":"2022022612090584700_gfaa219-B24","doi-asserted-by":"crossref","first-page":"e40465","DOI":"10.1371\/journal.pone.0040465","article-title":"Estrogen regulates hepcidin expression via GPR30-BMP6-dependent signaling in hepatocytes","volume":"7","author":"Ikeda","year":"2012","journal-title":"PLoS One"},{"key":"2022022612090584700_gfaa219-B25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1172\/JCI83831","article-title":"Progesterone receptor membrane component-1 regulates hepcidin biosynthesis","volume":"126","author":"Li","year":"2015","journal-title":"J Clin Invest"},{"key":"2022022612090584700_gfaa219-B26","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/acel.12052","article-title":"Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells","volume":"12","author":"Guo","year":"2013","journal-title":"Aging Cell"},{"key":"2022022612090584700_gfaa219-B27","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/01.tp.0000173791.42893.08","article-title":"Predictive factors of anemia within the first year post renal transplant","volume":"80","author":"Turkowski-Duhem","year":"2005","journal-title":"Transplantation"},{"key":"2022022612090584700_gfaa219-B28","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/ctr.12813","article-title":"Spectrum of anemia after kidney transplantation: pathophysiology and therapeutic implications","volume":"30","author":"Bamgbola","year":"2016","journal-title":"Clin Transplant"},{"key":"2022022612090584700_gfaa219-B29","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.transproceed.2008.03.080","article-title":"An underappreciated problem in renal transplant recipients: anemia","volume":"40","author":"Unal","year":"2008","journal-title":"Transplant Proc"},{"key":"2022022612090584700_gfaa219-B30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1681\/ASN.2011060546","article-title":"The complete correction of post-transplant anemia improves graft survival: results of multicenter randomized study","volume":"23","author":"Choukroun","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022022612090584700_gfaa219-B31","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ndt\/gfy365","article-title":"The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial","volume":"34","author":"Tsujita","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2022022612090584700_gfaa219-B32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1432-2277.2008.00814.x","article-title":"Iron deficiency and iron losses after renal transplantation","volume":"22","author":"Zheng","year":"2009","journal-title":"Transpl Int"},{"key":"2022022612090584700_gfaa219-B33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6061\/clinics\/2014(Sup01)03","article-title":"New immunosuppressive agents in pediatric transplantation","volume":"69","author":"Nguyen","year":"2014","journal-title":"Clinics (Sao Paulo"},{"key":"2022022612090584700_gfaa219-B34","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1016\/j.transproceed.2012.06.070","article-title":"Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease- another drawback of immunosuppression?","volume":"44","author":"Malyszko","year":"2012","journal-title":"Transplant Proc"},{"key":"2022022612090584700_gfaa219-B35","first-page":"99","article-title":"Hemolytic uremic syndrome after renal transplantation","volume":"10","author":"Vergoulas","year":"2006","journal-title":"Hippokratia"},{"key":"2022022612090584700_gfaa219-B36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2009.12.042","article-title":"The role of the renin-angiotensin system in the regulation of erythropoiesis","volume":"56","author":"Vlahakos","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2022022612090584700_gfaa219-B37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12882-018-1054-7","article-title":"Factors associated with anaemia in kidney transplant recipients in the first year after transplantation: a cross-sectional study","volume":"19","author":"Lim","year":"2018","journal-title":"BMC Nephrol"},{"key":"2022022612090584700_gfaa219-B38","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/jcm8091382","article-title":"Chronic use of proton-pump inhibitors and iron status in renal transplant recipients","volume":"8","author":"Douwes","year":"2019","journal-title":"J Clin Med"},{"key":"2022022612090584700_gfaa219-B39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1046\/j.1523-1755.2003.00850.x","article-title":"Post transplant erythrocytosis","volume":"63","author":"Vlahakos","year":"2003","journal-title":"Kidney Int"},{"key":"2022022612090584700_gfaa219-B40","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1016\/j.transproceed.2009.07.090","article-title":"Anemia and erythrocytosis after kidney transplantation: a 5-year graft function and survival analysis","volume":"41","author":"Kolonko","year":"2009","journal-title":"Transplant Proc"},{"key":"2022022612090584700_gfaa219-B41","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/qjmed\/hcv049","article-title":"Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis","volume":"108","author":"Cheungpasitporn","year":"2015","journal-title":"QJM"},{"key":"2022022612090584700_gfaa219-B42","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/gerona\/glt154","article-title":"Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin\/hemoglobin set point","volume":"69","author":"Bachman","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2022022612090584700_gfaa219-B43","article-title":"Androgens stimulate erythropoiesis through the DNA-binding activity of the androgen receptor in non-hematopoietic cells [published online ahead of print, 20 April 2020","author":"McManus","year":"2020","journal-title":"Eur J Haematol"},{"key":"2022022612090584700_gfaa219-B44","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1016\/j.transproceed.2014.07.070","article-title":"Incidence and management of leukopenia\/neutropenia in 233 kidney transplant patients following single dose alemtuzumab induction","volume":"46","author":"Smith","year":"2014","journal-title":"Transplant Proc"},{"key":"2022022612090584700_gfaa219-B45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.transproceed.2012.09.113","article-title":"The prevalence and risk factors of thrombocytopenia after living-related renal transplantation in chinese adult recipients","volume":"45","author":"Xie","year":"2013","journal-title":"Transplant Proc"},{"key":"2022022612090584700_gfaa219-B46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9429265","article-title":"Drug-induced hematological cytopenia in kidney transplantation and the challenges it poses for kidney transplant physicians","volume":"2018","author":"Khalil","year":"2018","journal-title":"J Transplant"},{"key":"2022022612090584700_gfaa219-B47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcell.2015.00018","article-title":"Blood disorders typically associated with renal transplantation","volume":"3","author":"Yang","year":"2015","journal-title":"Front Cell Dev Biol"},{"key":"2022022612090584700_gfaa219-B48","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1399-0012.2008.00893.x","article-title":"Management of leukopenia in kidney and pancreas transplant recipients","volume":"22","author":"Hartmann","year":"2008","journal-title":"Clin Transplant"},{"key":"2022022612090584700_gfaa219-B49","first-page":"1816","volume":"9"},{"key":"2022022612090584700_gfaa219-B50","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3389\/fphar.2018.01296","article-title":"Polymorphisms in mTOR and calcineurin signaling pathways are associated with long-term clinical outcomes in kidney transplant recipients","volume":"9","author":"Campos-Salazar","year":"2018","journal-title":"Front Pharmacol"},{"key":"2022022612090584700_gfaa219-B51","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/pbc.25215","article-title":"Treatment and outcomes of immune cytopenias following solid organ transplant in children","volume":"62","author":"Schoettler","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2022022612090584700_gfaa219-B52","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2022022612090584700_gfaa219-B53","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.transproceed.2013.10.030","article-title":"Incidence of post-transplantation lymphoproliferative disease in Andalusia (1990-2009)","volume":"45","author":"Govantes","year":"2013","journal-title":"Transplant Proc"},{"key":"2022022612090584700_gfaa219-B54","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.21911","article-title":"Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States","volume":"86","author":"Quinlan","year":"2011","journal-title":"Am J Hematol"},{"key":"2022022612090584700_gfaa219-B55","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1600-6143.2011.03896.x","article-title":"Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas","volume":"12","author":"Caillard","year":"2012","journal-title":"Am J Transplant"},{"key":"2022022612090584700_gfaa219-B56","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1034\/j.1399-3046.2002.00021.x","article-title":"Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study","volume":"6","author":"Dharnidharka","year":"2002","journal-title":"Pediatr Transplant"},{"key":"2022022612090584700_gfaa219-B57","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/TP.0000000000001201","article-title":"Posttransplant lymphoproliferative disorders in irish renal transplant recipients: insights from a National Observational Study","volume":"101","author":"O\u2019Regan","year":"2017","journal-title":"Transplantation"},{"key":"2022022612090584700_gfaa219-B58","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfx356","article-title":"Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study","volume":"33","author":"Francis","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2022022612090584700_gfaa219-B59","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N Engl J Med"},{"key":"2022022612090584700_gfaa219-B60","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/cid\/cit391","article-title":"Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"57","author":"Styczynski","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022022612090584700_gfaa219-B61","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/bmt.2013.170","article-title":"EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era","volume":"49","author":"Fox","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"2022022612090584700_gfaa219-B62","doi-asserted-by":"crossref","first-page":"e13145","DOI":"10.1111\/tid.13145","article-title":"Survival outcomes of allogeneic hematopoietic cell transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study","volume":"21","author":"Naik","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"2022022612090584700_gfaa219-B63","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.bbmt.2013.07.013","article-title":"Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022612090584700_gfaa219-B64","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00277-019-03742-7","article-title":"Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies","volume":"98","author":"Gao","year":"2019","journal-title":"Ann Hematol"},{"key":"2022022612090584700_gfaa219-B65","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) Guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"2022022612090584700_gfaa219-B66","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3109\/0284186X.2013.844853","article-title":"A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival","volume":"53","author":"Kinch","year":"2014","journal-title":"Acta Oncol"},{"key":"2022022612090584700_gfaa219-B67","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1097\/01.TP.0000144333.19106.58","article-title":"Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry","volume":"78","author":"Aull","year":"2004","journal-title":"Transplantation"},{"key":"2022022612090584700_gfaa219-B68","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.3109\/10428194.2013.780655","article-title":"Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors","volume":"54","author":"Dierickx","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2022022612090584700_gfaa219-B69","doi-asserted-by":"crossref","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","article-title":"NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019","volume":"17","author":"Zelenetz","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2022022612090584700_gfaa219-B70","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022022612090584700_gfaa219-B71","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3324\/haematol.2012.074500","article-title":"The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder","volume":"98","author":"Dierickx","year":"2013","journal-title":"Haematologica"},{"key":"2022022612090584700_gfaa219-B72","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/10428194.2013.813501","article-title":"18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in diagnosis of post-transplant lymphoproliferative disorder","volume":"55","author":"Panagiotidis","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2022022612090584700_gfaa219-B73","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/TP.0000000000002006","article-title":"End-of-treatment positron emission tomography after uniform first-line therapy of B-Cell posttransplant lymphoproliferative disorder identifies patients at low risk of relapse in the Prospective German PTLD Registry","volume":"102","author":"Zimmermann","year":"2018","journal-title":"Transplantation"},{"key":"2022022612090584700_gfaa219-B74","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"2022022612090584700_gfaa219-B75","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/ajt.13086","article-title":"International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial","volume":"15","author":"Trappe","year":"2015","journal-title":"Am J Transplant"},{"key":"2022022612090584700_gfaa219-B76","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"2022022612090584700_gfaa219-B77","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2012.43.2344","article-title":"Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score","volume":"31","author":"Caillard","year":"2013","journal-title":"J Clin Oncol"},{"key":"2022022612090584700_gfaa219-B78","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1470-2045(11)70300-X","article-title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","volume":"13","author":"Trappe","year":"2012","journal-title":"Lancet Oncol"},{"key":"2022022612090584700_gfaa219-B79","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial","volume":"35","author":"Trappe","year":"2017","journal-title":"J Clin Oncol"},{"key":"2022022612090584700_gfaa219-B80","article-title":"Post-transplant lymphoproliferative disorder: risk factors and management","author":"Malyszko","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2022022612090584700_gfaa219-B81","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2022022612090584700_gfaa219-B82","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ejh.12288","article-title":"Acute myeloid leukemia following solid organ transplantation: entity or novelty?","volume":"92","author":"Rashidi","year":"2014","journal-title":"Eur J Haematol"},{"key":"2022022612090584700_gfaa219-B83","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2014.132","article-title":"Risk of myeloid neoplasms after solid organ transplantation","volume":"28","author":"Morton","year":"2014","journal-title":"Leukemia"},{"key":"2022022612090584700_gfaa219-B84","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/leu.2011.224","article-title":"Commentary: does immune suppression increase risk of developing acute myeloid leukemia?","volume":"26","author":"Gale","year":"2012","journal-title":"Leukemia"},{"key":"2022022612090584700_gfaa219-B85","doi-asserted-by":"crossref","first-page":"e13052","DOI":"10.1111\/ctr.13052","article-title":"Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation","volume":"31","author":"Lontos","year":"2017","journal-title":"Clin Transplant"},{"key":"2022022612090584700_gfaa219-B86","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11095-019-2654-z","article-title":"Recent treatment advances and the role of nanotechnology, combination products, and immunotherapy in changing the therapeutic landscape of acute myeloid leukemia","volume":"36","author":"Chen","year":"2019","journal-title":"Pharm Res"},{"key":"2022022612090584700_gfaa219-B87","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-018-0085-4","article-title":"Myelodysplastic syndromes current treatment algorithm 2018","volume":"8","author":"Steensma","year":"2018","journal-title":"Blood Cancer J"},{"key":"2022022612090584700_gfaa219-B88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bcp.2017.11.022","article-title":"Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo","volume":"148","author":"Su","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"2022022612090584700_gfaa219-B89","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"2022022612090584700_gfaa219-B90","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"2022022612090584700_gfaa219-B91","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/sj.ki.5000352","article-title":"Nephrotic syndrome associated with hemophagocytic syndrome","volume":"69","author":"Thaunat","year":"2006","journal-title":"Kidney Int"},{"key":"2022022612090584700_gfaa219-B92","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.TP.0000107285.86939.37","article-title":"Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature","volume":"77","author":"Karras","year":"2004","journal-title":"Transplantation"},{"key":"2022022612090584700_gfaa219-B93","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1093\/ndt\/gfp282","article-title":"Haemophagocytic syndrome\u2013a life-threatening complication of renal transplantation","volume":"24","author":"Ponticelli","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2022022612090584700_gfaa219-B94","first-page":"322","article-title":"High-dose immunoglobulin therapy in renal transplant recipients with hemophagocytic histiocytic syndrome","volume":"19","author":"Asci","year":"2006","journal-title":"J Nephrol"},{"key":"2022022612090584700_gfaa219-B95","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/his.13855","article-title":"Clinical-pathological correlations in post-transplant thrombotic microangiopathy","volume":"75","author":"Broecker","year":"2019","journal-title":"Histopathology"},{"key":"2022022612090584700_gfaa219-B96","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.blre.2014.09.001","article-title":"De novo thrombotic microangiopathy after non-renal solid organ transplantation","volume":"28","author":"Verbiest","year":"2014","journal-title":"Blood Reviews"},{"key":"2022022612090584700_gfaa219-B97","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","article-title":"De novo thrombotic microangiopathy after kidney transplantation","volume":"32","author":"Garg","year":"2018","journal-title":"Transplant Rev (Orlando)"},{"key":"2022022612090584700_gfaa219-B98","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1076029615598221","article-title":"Hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"22","author":"Elsallabi","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"2022022612090584700_gfaa219-B99","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1432-2277.2006.00354.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"19","author":"Ponticelli","year":"2006","journal-title":"Transplant Int"},{"key":"2022022612090584700_gfaa219-B100","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.transproceed.2012.07.039","article-title":"De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival","volume":"44","author":"Caires","year":"2012","journal-title":"Transplant Proc"},{"key":"2022022612090584700_gfaa219-B101","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"2022022612090584700_gfaa219-B102","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2022022612090584700_gfaa219-B103","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bjh.15647","article-title":"A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline","volume":"184","author":"Mcmullin","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/3\/409\/42619239\/gfaa219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/3\/409\/42619239\/gfaa219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T12:10:12Z","timestamp":1645877412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/3\/409\/5956379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":103,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,5]]},"published-print":{"date-parts":[[2022,2,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa219","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3]]},"published":{"date-parts":[[2020,11,5]]}}}